Regulatory Context for Compounded GLP-1 Medications February 2025 The FDA announced that the semaglutide shortage had been resolved, which resulted in changes to compounding permissions for pharmacies
-
Results vary based on factors such as insulin resistance, hormonal balance, and how closely the treatment plan is followed
Suhail Jamil, Superintendent Pharmacist at Ashcroft Pharmacy , said: Many are assuming that the tablet will be the most convenient option, but that wont necessarily be the case
In practical terms, that likely means a provider would first send a prescription for an eligible GLP-1 medication to a participating pharmacy, which would then process the claim using the bridge programs billing information
In all the clinical trials between the two classes of medications, only sitagliptin has been studied in direct comparisons with a GLP-1RA